Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD), AbbVie Inc (ABBV): Which Company Needs a HCV Win?

Page 1 of 2

The upcoming all-oral hepatitis C treatments earned well-deserved attention for some staggering cure rates, particularly in patient groups who haven’t responded well to the current drugs. Merck & Co., Inc. (NYSE:MRK) was one of the big HCV players — but that’s about to change with Gilead Sciences, Inc. (NASDAQ:GILD) and AbbVie Inc (NYSE:ABBV) leading the new guard. How much does an HCV foothold mean to the overall health of these companies?

Gilead Sciences, Inc. (NASDAQ:GILD)

Defending champion falls flat

The combo therapy used for most patients with ongoing HCV involves an interferon injection and the oral drug ribavirin. But patients with genotype 1 — the most common genotype in the United States — require the addition of a protease inhibitor to achieve the best possible cure rates.

Merck & Co., Inc. (NYSE:MRK) has historically held a front position in the HCV market with the ribavirin Rebetol, the branded interferon PegIntron, and the protease inhibitor Victrelis. But generic ribavirin became available nearly a decade ago — and Merck & Co., Inc. (NYSE:MRK)’s lost most of its other ground to competitors.

PegIntron hit peak sales of $914 million in 2008 when Schering Plough was still independent. Sales last year had fallen to $653 million due to the rise of Roche’s competing Pegasys, which had 2012 sales of about $1.7 billion (using current exchange rates).

Victrelis was much faster at succumbing to competition. The drug launched concurrently with Vertex’s protease inhibitor Incivek in 2011. Incivek quickly took the market with sales of $950 million in 2011 and $1.16 billion in 2012. Victrelis had sales of $140 million and $502 million, respectively. But both protease inhibitors could suffer a massive drop when the all-oral drugs hit the market.

New guard’s drug dependence

Three companies have reported the best cure rates for genotype 1 patients: Gilead Sciences, Inc. (NASDAQ:GILD), AbbVie Inc (NYSE:ABBV), and Johnson and Johnson.

Let’s turn first to Gilead Sciences, Inc. (NASDAQ:GILD)’s sofosbuvir. The drug received a priority review designation from the Food and Drug Administration last month and has an expected PDUFA date of December 8.. Analyst estimates for sofosbuvir average out to around $6 billion by 2016, according to Bloomberg.

Gilead Sciences, Inc. (NASDAQ:GILD)’s total products sales were $9.4 billion last year and that included over a dozen products. The company’s portfolio includes a strong batch of HIV drugs, while the pipeline also features some promising cancer candidates.

AbbVie Inc (NYSE:ABBV)’s unnamed oral combo-therapy is running slightly behind Gilead Sciences, Inc. (NASDAQ:GILD) in the pipelines, but AbbVie Inc (NYSE:ABBV)’s in greater need of a win.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!